Nebilenin (Nebivolol Hydrochloride)

Nebivolol blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility, which lowers cardiac output. At the same time, it enhances nitric oxide release from the endothelium, causing vasodilation of peripheral vessels. This dual action reduces systemic vascular resistance and contributes to blood pressure reduction.

The appropriate dose of Nebilenin is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any comorbidities. Dosage adjustments may be required for patients with renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To request Nebilenin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nebilenin (nebivolol) is a third‑generation beta blocker that offers selective β1 antagonism combined with nitric‑oxide‑mediated vasodilation, which may provide better tolerability and fewer metabolic side effects compared with older non‑selective agents. Its unique vasodilatory property can be advantageous in patients who experience peripheral vasoconstriction with other beta blockers.

Nebilenin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Nebilenin is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise instructed by a healthcare professional.

Serious risks include severe bradycardia, atrioventricular block, acute heart failure exacerbation, and rare allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid weight gain, shortness of breath, or signs of an allergic response.

Nebilenin is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure. Clinicians should also exercise caution in patients with asthma or severe chronic obstructive pulmonary disease.